SEC Tracker
Get the app

KLA KLAC

KLA Q2 FY26: revenue $3.3B, up 7%; diluted EPS $0.00

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers KLA reported for Q2 FY26, the quarter ended Dec 31, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$3.3B+7% from $3.1B in Q2 FY2510-Q income statement, on EDGAR
  2. Net income$1.1B+39% from $824.5M in Q2 FY2510-Q income statement, on EDGAR
  3. Diluted EPS$0.00Flat against $0.00 in Q2 FY25. Split-adjusted, as the tables show it; the filing reported $8.6810-Q income statement, on EDGAR
  4. Cash and cash equivalents$2.5B+33% from $1.8B in Q2 FY2510-Q balance sheet, on EDGAR
  5. Cash from operations$1.4B+61% from $849.5M in Q2 FY2510-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when KLA files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3827 and related industry codes: the same peer list as the financial tables.

  1. Thermo Fisher Scientific TMO public float $154.0B, Jun 27, 2025
  2. Danaher DHR public float $125.9B, Jun 30, 2025
  3. Trane Technologies TT public float $97.2B, Jun 30, 2025
  4. Roper Technologies ROP public float $60.8B, Jun 30, 2025
  5. Ametek AME public float $41.8B, Jun 30, 2025